- Genomic Vision’s advanced fluorescence scanner,
FiberVision®S, and new FiberSmart® software to support research at
The Institute of Cancer Research (ICR)
- Further validation of Genomic Vision’s suite of technology
and software applications which accelerate research and development
outcomes
- Agreement to provide annual recurring revenue from sales of
consumables associated with FiberVision®S and FiberSmart®
Regulatory News:
Genomic Vision (FR0011799907 – GV, – the “Company”), a
Euronext-listed biotechnology company that develops products and
services for the highly accurate characterization of DNA sequences,
today announces an agreement with The Institute of Cancer Research,
London, for the purchase of the Company’s FiberVision®S and
FiberSmart® products. The agreement includes an upfront, one-off
payment in addition to annual recurring revenues from sales of
consumable products related to FiberVision®S and FiberSmart®.
The ICR is a world-leading research organization dedicated to
understanding the causes and mechanisms of cancer, developing new
treatment approaches, and improving patient outcomes. FiberVision®S
and FiberSmart® will be used by the ICR’s scientists to expedite
cancer research activities to gain molecular insights into complex
biological processes, the findings of which will translate into
clinical applications.
FiberVision®S is a state-of-the-art fluorescence scanner for
Molecular Combing, developed for Life Science research applications
of single DNA molecule analysis. FiberSmart® uses advanced AI
algorithms for the analysis of Replication Combing Assays (RCA),
Genomic Vision’s proprietary method for the direct visualization of
DNA replication kinetics at the single molecule level. Together
these applications are essential tools for the development of new
drugs.
Oncology is a highly competitive research area, driven by an
increasing incidence of cancer worldwide. Monitoring the features
of genomic instability, a hallmark of cancer development, is
crucial to better understand these complex molecular mechanisms.
For several years, DNA fiber analysis/RCA has been established as a
gold standard approach to decipher the global DNA metabolism and
more precisely to evaluate the replication stress induced by any
genotoxic agent, such as anticancer chemotherapy compounds and
radiation therapies. By providing unique added-value services
Genomic Vision helps the scientific community to gain molecular
insights into these complex biological processes and optimize drug
development accordingly.
Aaron Bensimon, Chief Executive Officer of Genomic Vision,
commented: “Our proprietary technologies offer significant
value-add to the drug discovery process. Our services help to
de-risk development, shorten timelines, reduce costs and ultimately
optimize outcomes for patients and companies. This is further
evidenced by our growing roster of clients across industry and
academia, including The Institute of Cancer Research, renowned for
its excellence in drug discovery. We look forward to working with
the ICR and to playing some part in future scientific
breakthroughs.”
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company that develops products
and services for the highly accurate characterization of genome
modifications. We deliver high-quality integrated genomic analysis
solutions to improve quality control and bioproduction standards of
advanced gene therapies at scale. Based on molecular combing
technology and artificial intelligence, The Company provides robust
quantitative measurements needed for high confidence
characterization of transformed cell lines and prediction of cell
line performance, in particular in the context of the
biomanufacturing processes of cell and gene therapies. Genomic
Vision’s molecular combing technology has further applications in
drug development of agents targeting DNA replication and damage
response mechanisms, visualizing DNA replication kinetics and
telomere length maintenance. Genomic Vision, based near Paris in
Bagneux, is a public company listed in compartment C of Euronext’s
regulated market in Paris (Euronext: GV – ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
ABOUT ICR
The Institute of Cancer Research, London, is one of the world’s
most influential cancer research institutes, with an outstanding
record of achievement dating back more than 100 years. Around 800
scientists work at ICR across the full spectrum of cancer research,
from basic cancer biology to clinical trials. The ICR ranked second
in REF 2021, the UK government’s most recent comprehensive
assessment of research quality, for overall research quality and
impact, and first in biological sciences.
The ICR is also one of the world’s most successful academic
institutions in industry collaboration and is especially well-known
for its excellence in drug discovery. Researchers in the ICR’s
Centre for Cancer Drug Discovery, have discovered 21 drug
candidates since 2005, of which 13 have progressed into clinical
trials, in collaboration with industry partners. The blockbuster
drug abiraterone (Zytiga®) was discovered and initially developed
at the ICR, and ICR science also underpinned the development of the
leading PARP inhibitor olaparib (Lynparza®) in BRCA-mutant
cancers.
The ICR and its hospital partner The Royal Marsden NHS
Foundation Trust are together ranked in the top four centers for
cancer research and treatment worldwide, and their joint Drug
Development Unit is the leading oncology-focused phase I trial unit
in the UK. The ICR is also a provider of higher education of
international distinction through its postgraduate degree
programs.
Member of the CAC® Mid & Small and CAC® All-Tradable
indices
FORWARD LOOKING STATEMENT
Genomic Vision has set up a financing line in the form of
convertible notes with warrants (OCABSA) with Winance, which does
not intend to remain a shareholder of the company, after receiving
the shares resulting from the conversion or exercise of the
securities.
The shares resulting from the conversion or exercise of the
aforementioned securities will, in general, be sold on the market
very quickly, which is likely to create strong downward pressure on
the share price as well as a strong dilution.
Shareholders could therefore suffer a loss of their invested
capital due to a significant decrease in the value of the company's
shares. The company has carried out several dilutive financing
operations, and investors are advised to be very careful before
making a decision to invest in the company's securities.
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the universal
registration document filed with the AMF on April 28, 2023 under
number D.23-0383, available on the web site of Genomic Vision
(www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230619156541/en/
Genomic Vision Aaron Bensimon Chairman of the Management
Board Tel.: +33 1 49 08 07 51 investisseurs@genomicvision.com
Ulysse Communication Media Relations Bruno Arabian Tél.:
+33 1 42 68 29 70 barabian@ulysse-communication.com
Consilium Strategic Communications International Investor
Relations & Strategic Communications Tel.: +44 (0) 20 3709 5700
GenomicVision@consilium-comms.com
NewCap France Investor Relations & Strategic
Communications Tel.: +33 1 44 71 94 94 gv@newcap.eu
Guerrero Ventures (TSXV:GV)
過去 株価チャート
から 4 2024 まで 5 2024
Guerrero Ventures (TSXV:GV)
過去 株価チャート
から 5 2023 まで 5 2024
